2N Pharma Holding ApS: Financial statements 2024
CVR: 42523453
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
2N Pharma Holding ApS (CVR 42523453) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -38,812 and a net result of DKK -1,033,166 compared with DKK -948,734 the year before. Equity in the 2024 report amounted to DKK -2,165,476.
- Gross Profit
- DKK -38,812
- Profit/Loss
- DKK -1,033,166
- Equity
- DKK -2,165,476
- Total Assets
- DKK 11,284,504
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -39 t. | -1 mio. | -2.2 mio. | - |
| 2023 | - | -31 t. | -949 t. | -1.1 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
2N Pharma Holding ApS has published its annual report for 2023. Gross profit came to DKK -31,303, and the net result was DKK -948,734.
About 2N Pharma Holding ApS
2N Pharma Holding ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2021. The company is under bankruptcy. The company is registered under the industry Ikke-finansielle holdingselskaber. The company is owned by Neurometa Therapeutics AB. In 2024, the company reported a gross profit of DKK -38,812 and a net result of DKK -1,033,166 compared with DKK -948,734 the year before. Equity in the 2024 report amounted to DKK -2,165,476.